1. Opening Hook
If chemistry had a LinkedIn page, Acutaas Chemicals just updated its headline to “Now hiring: Batteries, Semiconductors & Global Ambition.” The once humble pharma-intermediate maker is now flirting with Korean tech partners and lithium-ion dreams — all while casually doubling profits.
Revenue’s exploding, margins are glowing, and CMD Naresh Patel now sounds like he’s auditioning for Breaking Bad: Season Corporate.
Stay tuned — they’ve got solar plants powering reactors, Koreans funding fabs, and CFOs flexing working capital like gym bros with spreadsheets. 🔥
2. At a Glance
- Revenue ₹306 Cr (+24%) – Chemistry’s on steroids; everything grew except modesty.
- EBITDA ₹95 Cr (+2x YoY) – When molecules align, margins follow.
- PAT ₹72 Cr (+91%) – Profits so shiny they need lab goggles.
- EBITDA Margin 31.1% – Every CFO’s Diwali wish come true.
- Capex ₹141 Cr (H1) – Cash turned into reactors, not regrets.
- Cash Reserves ₹240 Cr – Enough to build another lab or buy one.
- Working Capital Days 100 (↓28) – The inventory gods have finally smiled.
3. Management’s Key Commentary
Naresh Patel (CMD): “We’re building long-term sustainable business rather than chasing opportunities.”
(Translation: Unlike the crypto crowd, we read balance sheets.)
On Battery Chemicals: “Production to start Q4 FY26 after capex completion.”
(Translation: The lithium-ion dream finally leaves the PowerPoint slide.)
On Semiconductor JV: “Indichem in Korea will start contributing by H2 FY27.”
(Translation: Seoulmates in science, not just in sentiment.)
Abhishek Patel (VP Strategy): “Pharma Intermediates grew 27%, Specialty Chemicals 7%.”
(Translation: Old business feeds us, new ones fund our TED Talks.)
Bhavin Shah (CFO): “Gross margins up 1,232 bps to 55.8%.”
(Translation: We printed chemistry money.)
Abhishek Patel: “We
